Dr. Perry is a Senior Director in the Structural Biology & Chemistry Department of Gilead Sciences, Inc., where he has been since 2006. A computational chemist by training, he has been a contributor to over 25 drug discovery programs and served as project leader in three discovery efforts. With a primary focus on antivirals, he has contributed to the discovery and development of multiple approved drugs, including cures for hepatitis C (sofosbuvir, ledipasvir and velpatasvir) and the first clinically approved treatment for COVID-19 (remdesivir). He is a co-author on 50 peer-reviewed publications, including 19 since the start of the pandemic focusing on a structural understanding of coronavirus replication and inhibition. Prior to joining Gilead, he worked at the software company, Schrodinger, Inc., where he was the company’s first application scientist and assisted in the development of its quantum mechanics software, Jaguar, and its docking software, Glide. He received his B.A. in Chemistry at Johns Hopkins University and his Ph.D. in Chemistry at the California Institute of Technology, where he worked in the labs of William A. Goddard III.